Pfizer trispecific antibody tilrekimig meets Phase 2 atopic dermatitis endpoint

Atopic dermatitis is one of the most common chronic inflammatory skin diseases, and for adults who live with the moderate-to-severe form, the condition often means persistent itch, disrupted sleep and limited treatment options that deliver complete skin clearance. For years the standard of care for biologic therapy has centered on blocking a single cytokine pathway, most commonly interleukin-4 and interleukin-13 signaling. That approach has helped many patients, yet a substantial share still do not reach clear or almost clear skin, which has pushed drugmakers to look for ways to shut down more than one inflammatory driver at once.

Pfizer Inc. (NYSE: PFE) on October 1, 2026, presented detailed results from an ongoing Phase 2 study of tilrekimig (PF-07275315), an investigational trispecific antibody, in adults with moderate-to-severe atopic dermatitis. The company said the trial met its primary endpoint, with a statistically significant increase in the percentage of participants achieving EASI-75, defined as at least a 75% reduction in the Eczema Area and Severity Index, at week 16 across all evaluated doses compared with placebo. The findings were shared in an oral presentation at the 35th European Academy of Dermatology and Venereology Annual Congress in Vienna, Austria.

Tilrekimig is described by Pfizer as a potential first-in-class trispecific antibody that simultaneously inhibits upstream and downstream drivers of type 2 inflammation through concurrent high-affinity binding to interleukin-4, interleukin-13 and thymic stromal lymphopoietin. By directly blocking TSLP together with its downstream effectors, the antibody is designed to provide broader cytokine pathway coverage and potentially more durable clinical responses. The molecule is also engineered to have an extended half-life of about 37 days, which Pfizer anticipates will support monthly administration.

The readout places Pfizer in a crowded race among next-generation atopic dermatitis biologics, where companies are testing half-life extended antibodies and multi-pathway approaches to improve on the efficacy and convenience of existing injectable therapies. It also arrives as Pfizer works to rebuild momentum in its inflammation and immunology portfolio.

Key Facts

Business Wire reported on October 1, 2026, that the Phase 2 study evaluated tilrekimig in adults with moderate-to-severe atopic dermatitis and met its primary endpoint of EASI-75 at week 16 across all doses tested. According to the detailed data, the trial is an ongoing randomized, double-blind, placebo-controlled study, and the results reflect the first two stages, both of which enrolled biologic-naive patients.

Dermatology Times reported on October 1, 2026, that at week 16, 47.8% to 62.5% of adults receiving tilrekimig achieved EASI-75 across doses, compared with 9.1% to 19.9% for placebo. In Stage 1, 62.5% of patients receiving subcutaneous tilrekimig 450 mg every two weeks reached EASI-75 at week 16 versus 19.9% on placebo, with a P value of .0008. Stage 2 was a dose-ranging evaluation of 400 mg, 200 mg or 50 mg given every four weeks, and EASI-75 was achieved by 58.5%, 61.0% and 47.8% of patients respectively, against 9.1% on placebo, with all P values below .003. The absolute improvements over placebo were 49.4, 51.9 and 38.7 percentage points.

HCPLive reported on October 1, 2026, that tilrekimig is a trispecific antibody targeting interleukin-4, interleukin-13 and thymic stromal lymphopoietin, and that it met the EASI-75 endpoint at every dose evaluated. The outlet also noted that the molecule has a half-life of about 37 days, a profile expected to support monthly dosing, and that it joins other next-generation atopic dermatitis biologics presented at the Vienna congress, including the half-life extended interleukin-13 antibody zumilokibart.

Secondary and exploratory endpoints reinforced the primary result. On the key secondary endpoint of vIGA 0/1 with at least a two-point improvement, Stage 1 produced 30.3% for tilrekimig versus 11.8% for placebo (P = .0251), while Stage 2 produced 26% to 27% versus 0% (all P values below .006). Exploratory PP-NRS4 responses, meaning at least a four-point reduction in itch, were 42.5% at 400 mg every four weeks and 50.8% at 200 mg every four weeks, compared with 7.2% on placebo.

On safety, Pfizer characterized tilrekimig as well tolerated, with no dose-dependent safety signals and treatment-emergent adverse event rates comparable to placebo. Stage 1 treatment-emergent adverse events occurred in 46.7% of patients on 450 mg every two weeks versus 28.9% on placebo, while in Stage 2 the range was 42.2% to 47.8% versus 52.2% for placebo. No serious adverse events related to tilrekimig occurred. At doses up to 400 mg every four weeks, conjunctivitis and injection-site reaction rates were lower than those seen with IL-4 receptor alpha inhibitors and comparable to placebo.

Analysis

The bigger picture here is that Pfizer has produced a credible proof of concept for a multi-pathway antibody in a disease where single-pathway blockade, however effective, leaves a meaningful share of patients short of clear skin. The absolute improvements over placebo in the monthly dosing arms, from 38.7 to 51.9 percentage points, are large for a Phase 2 atopic dermatitis study and compare favorably with what has been reported for some approved biologics. The fact that all evaluated doses separated from placebo with P values below .003 also suggests the effect is not an artifact of a single dose or a single schedule.

Just as important is the design story. Tilrekimig binds interleukin-4, interleukin-13 and thymic stromal lymphopoietin simultaneously. TSLP sits upstream in the inflammatory cascade, while IL-4 and IL-13 are downstream effectors, so blocking all three is meant to cut off the pathway at multiple points rather than relying on one node. Whether that translates into deeper or more durable responses over a longer period cannot be answered by 16-week data, but the mechanism is coherent and the early numbers support it. The roughly 37-day half-life, if confirmed in larger studies, would allow monthly dosing, a convenience advantage in a market where patients often weigh injection burden alongside efficacy.

The tolerability profile also matters. Conjunctivitis and injection-site reactions have been persistent talking points for IL-4 receptor alpha inhibitors, and Pfizer reported that rates at doses up to 400 mg every four weeks were lower than that benchmark and comparable to placebo. No treatment-related serious adverse events were reported. That is a promising signal, though Phase 2 safety databases are far smaller than the thousands of patients exposed in Phase 3 programs, and rare events can take years to surface.

The competitive context is worth stating plainly. HCPLive noted that tilrekimig was presented alongside other next-generation atopic dermatitis biologics at the same congress, including zumilokibart. Pfizer has also moved quickly: the company said it has dosed patients in three Phase 3 trials, two in atopic dermatitis, including one with dupilumab as an active comparator, plus work in asthma and a Phase 2b/3 study in chronic obstructive pulmonary disease. An active-comparator design against dupilumab is a high bar and a clear statement that Pfizer intends to compete on efficacy, not just convenience.

Why It Matters

For patients with moderate-to-severe atopic dermatitis, the practical question is not whether a new mechanism exists but whether it delivers clear skin, controls itch and can be tolerated for years. The reported EASI-75 rates of 47.8% to 62.5% at week 16 and the itch reductions of 42.5% to 50.8% are meaningful on both counts, though the true test will be durability, since atopic dermatitis is a chronic condition that requires long-term control. If the Phase 3 program reproduces these results, tilrekimig could offer an alternative for people who do not respond adequately to existing therapies.

For Pfizer, the readout is a validation of its inflammation and immunology strategy at a time when the company needs pipeline wins. Michael Vincent, M.D., Ph.D., chief inflammation and immunology officer at Pfizer, said the compelling efficacy and tolerability demonstrated in the Phase 2 study validate the multi-pathway, trispecific approach, adding that Pfizer has initiated Phase 3 trials of tilrekimig in atopic dermatitis and asthma and is advancing a Phase 2b/3 study in COPD. Eric Simpson, MD, MCR, of the department of dermatology at Oregon Health & Science University, said the week 16 results are meaningful at this stage of development, with a tolerability profile supporting continued study in a larger population.

The broader industry implication is that trispecific and multi-specific antibodies may become a durable design trend in immunology. The approach trades the simplicity of single-target blockade for broader pathway coverage, and if it holds up, it could reshape how companies think about the next generation of inflammatory disease drugs. It also raises the competitive stakes in atopic dermatitis, asthma and COPD, three large markets where differentiated efficacy, dosing intervals and safety profiles will determine commercial success.

Next Up

Pfizer said it has initiated Phase 3 trials of tilrekimig in atopic dermatitis and asthma and is advancing a Phase 2b/3 study in COPD. HCPLive reported on October 1, 2026, that the company has dosed patients in three Phase 3 trials, two in atopic dermatitis, including one with dupilumab as an active comparator. Those studies will need to show that the week 16 gains seen in Phase 2 translate into durable responses over 52 weeks and beyond, and that the safety profile holds in a much larger population.

Additional data, including longer-term maintenance results and the COPD readout, will shape how tilrekimig is positioned. For now, the Phase 2 results give Pfizer a credible first-in-class candidate and give clinicians one more reason to watch the next-generation atopic dermatitis pipeline closely.